VIP
Also known as: Vasoactive Intestinal Peptide
A neuropeptide with anti-inflammatory and tissue-protective properties.
Overview
Vasoactive Intestinal Peptide is a 28-amino acid neuropeptide with widespread tissue distribution. It acts as a neurotransmitter and neuromodulator with potent anti-inflammatory and cytoprotective effects.
Mechanism of Action
VIP binds VPAC1 and VPAC2 receptors, activating cAMP pathways. Inhibits pro-inflammatory cytokine production, promotes regulatory T cells, and has direct neuroprotective effects.
Pharmacokinetics
Very short half-life (1-2 minutes in plasma). Often administered intranasally or via sustained-release formulations.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Intranasal
50 mcg
4x daily
4-8 weeks
CIRS protocol
Subcutaneous
50-100 mcg
Once daily
4 weeks
Systemic anti-inflammatory
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Reduced inflammation in rheumatoid arthritis models
- 2Neuroprotective in Parkinson's and Alzheimer's models
- 3Benefits in chronic inflammatory response syndrome (CIRS)
- 4Pulmonary vasodilator effects
Side Effects & Contraindications
Reported Side Effects
- Nasal irritation
- Flushing
- Hypotension
Contraindications
- Hypotension
- Cardiac conduction abnormalities
Safety Considerations
Generally well-tolerated. Hypotension possible with higher doses due to vasodilatory effects.
Storage Requirements
Store at 2-8C. Protect from light.
Scientific References
- 1